MedTrace Logo

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

NCT06992687 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-28

No results posted yet for this study

Summary

To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors

Conditions

Interventions

DRUG

HB0052 Injection

An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Hunan Cancer Hospital

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • The Second Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-09-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06992687 on ClinicalTrials.gov